
A circuit from the ventral subiculum to anterior hypothalamic nucleus GABAergic neurons essential for anxiety-like behavioral avoidance
简介:
- 作者: Jing-Jing Yan, Xiao-Jing Ding, Ting He, Ai-Xiao Chen, Wen Zhang, Zi-Xian Yu, Xin-Yu Cheng, Chuan-Yao Wei, Qiao-Dan Hu, Xiao-Yao Liu, Yan-Li Zhang, Mengge He, Zhi-Yong Xie, Xi Zha, Chun Xu, Peng Cao, Haohong Li, and Xiao-Hong Xu
- 杂志: Nat Commun
- Doi: https://www.doi.org/10.1038/s41467-022-35211-7
- 出版日期: 2022 Dec 3
论文中使用的产品/服务
Quotation shows PackGene:AAV- CAG-DIOGtACR1 (Serotype 2/5, titer 5.00 × 10^12 vg/mL) was purchased from PackGene Biotech Co, Guangzhou.
Research Field:CNS
AAV Serotype:AAV2/5
Targeted organ:brain
Animal or cell line strain:adult males aged between 8–30 weeks. Wildtype males of C57BL/6 J
摘要
Behavioral observations suggest a connection between anxiety and predator defense, but the underlying neural mechanisms remain unclear. Here we examine the role of the anterior hypothalamic nucleus (AHN), a node in the predator defense network, in anxiety-like behaviors. By in vivo recordings in male mice, we find that activity of AHN GABAergic (AHNVgat+) neurons shows individually stable increases when animals approach unfamiliar objects in an open field (OF) or when they explore the open-arm of an elevated plus-maze (EPM). Moreover, object-evoked AHN activity overlap with predator cue responses and correlate with the object and open-arm avoidance. Crucially, exploration-triggered optogenetic inhibition of AHNVgat+ neurons reduces object and open-arm avoidance. Furthermore, retrograde viral tracing identifies the ventral subiculum (vSub) of the hippocampal formation as a significant input to AHNVgat+ neurons in driving avoidance behaviors in anxiogenic situations. Thus, convergent activation of AHNVgat+ neurons serves as a shared mechanism between anxiety and predator defense to promote behavioral avoidance.
关于派真
作为一家专注于AAV 技术十余年,深耕基因治疗领域的CRO&CDMO,派真生物可提供从载体设计、构建到 AAV、慢病毒和 mRNA 服务的一站式解决方案。凭借深厚的技术实力、卓越的运营管理和高标准的服务交付,我们为全球客户提供一站式CMC解决方案,包括从早期概念验证、成药性评估到IIT、IND及BLA的各个阶段。
凭借我们独立知识产权的π-alphaTM 293 细胞AAV高产技术平台,我们能将AAV产量提高多至10倍,每批次产量可达1×10¹⁷vg,以满足多样化的商业化和临床项目需求。此外,我们定制化的mRNA和脂质纳米颗粒(LNP)产品及服务覆盖药物和疫苗开发的各个阶段,从研发到符合GMP的生产,提供端到端的一站式解决方案。
